Quick Takeaways
- MORGAN STANLEY filed SCHEDULE 13G/A for Tarsus Pharmaceuticals, Inc. Common Stock (TARS).
- Disclosed ownership: 4.7%.
- Date of event: 31 Mar 2025.
MORGAN STANLEY - 31 Mar 2025 SCHEDULE 13G/A Report for Tarsus Pharmaceuticals, Inc. Common Stock (TARS)
- Filing Manager
- MORGAN STANLEY
- Reporting Manager
- Morgan Stanley
- Symbol
- TARS
- Shares outstanding
- 41,350,064 shares
- Disclosed Ownership
- 1,943,453 shares
- Ownership
- 4.7%
- Form type
- SCHEDULE 13G/A
- Filing time
- 07 May 2025, 11:27:44 UTC
- Date of event
- 31 Mar 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"MORGAN STANLEY disclosed 4.7% ownership in Tarsus Pharmaceuticals, Inc. Common Stock (TARS) on 31 Mar 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 07 May 2025, 11:27.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | 4.7% | 1,943,453 | 0 | 1,932,256 | Christopher O'Hara | Authorized Signatory, Morgan Stanley |